Lydisilka is a combined hormonal contraceptive. It contains the active substances drospirenone and estetrol monohydrate.
Therapeutic Indication
### Therapeutic indication Oral contraception. The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Therapeutic Area (MeSH)
ATC Code
G03
ATC Item
性激素和生殖系统调节药
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
INN / Common Names
EMA Name
Lydisilka
Medicine Name
Lydisilka
Aliases
N/ANo risk management plan link.
